NCT05651282 2026-04-13
RESToRE
University of British Columbia
Phase 4 Completed
Clinical Trials
14 trialsNCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT05247268 2025-04-06
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Fudan University
Phase 2 Recruiting
NCT05255653 2024-11-29
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT02228681 2024-09-19
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT06549855 2024-08-12
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Peking University People's Hospital
Phase NA Not yet recruiting
NCT05675787 2024-07-11
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Peking University People's Hospital
Phase 2 Recruiting
NCT03018249 2021-11-16
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Completed
NCT03463252 2021-09-13
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
West China Second University Hospital
Phase 2/3 Recruiting
NCT03567655 2018-06-26
Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer
Asan Medical Center
Phase 2 Unknown
NCT02872818 2016-08-23
Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia
Kayseri Education and Research Hospital
Phase 4 Completed
NCT00064025 2016-04-11
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
GOG Foundation
Phase 2 Completed
NCT00739830 2015-07-01
Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00033358 2013-05-03
Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer
National Cancer Institute (NCI)
Phase 2 Completed